Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.48 |
| ▸ | FAAH | O00519 | 12/20 | 0.48 |
| ▸ | AADAC | P22760 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16570022 | 1.00 | EPHX2 (0.48) | EPHX2FAAHAADACRAF1FPR2 | |
| SCHEMBL7657873 | 0.91 | EPHX2 (0.54) | EPHX2FAAHAADACRAF1FPR2 | |
| SCHEMBL2013324 | 0.84 | PARP10 (0.47) | EPHX2 | |
| SCHEMBL18960369 | 0.83 | EPHX2 (0.48) | EPHX2FAAHAADACRAF1FPR2 | |
| SCHEMBL649802 | 0.82 | TEAD1 (0.52) | EPHX2FPR2PROKR1MMP2MMP13 | |
| SCHEMBL22731878 | 0.82 | TEAD1 (0.52) | EPHX2FPR2PROKR1MMP2MMP13 | |
| SCHEMBL648451 | 0.82 | TEAD1 (0.52) | EPHX2FPR2PROKR1MMP2MMP13 | |
| Hydrochloric Acid SCHEMBL30636292 | 0.82 | KDM1A (0.41) | EPHX2FAAHAADACFPR2PROKR1 | |
| Hydrochloric Acid SCHEMBL30152387 | 0.81 | TEAD1 (0.51) | EPHX2FPR2PROKR1MMP2MMP13 | |
| SCHEMBL1065750 | 0.79 | EPHX2 (0.50) | EPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | MADAR DAVID J | 2007-10-11 | — | — | US | disclosed |
| US-7238724-B2 | Antidiabetic agents; hyperlipemic agents; obestity; immunomoderator; atherosclerosis | ABBOTT LABORATORIES (US) | 2007-07-03 | — | — | US | disclosed |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | EIF2AK1, EIF2A, EIF4A2 | EPHX2 3905/4885FAAH 4078/4885AADAC 1796/4885 |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | EPHX2 2739/4885FAAH 3307/4885AADAC 306/4885 |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | EPHX2 2739/4885FAAH 3307/4885AADAC 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.